BACKGROUND
Seventy-seven patients diagnosed with advanced PD were recruited in an open longitudinal 36-month study at 10 clinics in Sweden and Norway; 40 of them were treated with levodopa-carbidopa intestinal gel (LCIG) and 37 patients were candidates for switching from oral PD treatment to LCIG [1, 2] . Patient characteristics at baseline are shown in Table 1 . They utilized a mobile device test battery, consisting of selfassessments of symptoms and objective measures of motor function through a set of fine motor tests (tapping and spiral drawings), in their homes (Fig 1) [3] . Both the LCIG-naïve and LCIG-non-naïve patients used the test battery four times per day during week-long test periods.
METHODS

ASSESSMENTS
The LCIG-naïve patients used the test battery at baseline (before LCIG), month 0 (first visit; at least 3 months after intraduodenal LCIG), and thereafter quarterly for the first year and biannually for the second and third years. The LCIG-non-naïve patients used the test battery from the first visit, i.e. month 0. Out of the 77 patients, only 65 utilized the test battery; 35 were LCIG-non-naïve and 30 LCIG-naïve. In 20 of the LCIG-naïve patients, assessments with the test battery were available during oral treatment and at least one test period after having started infusion treatment. Three LCIG-naïve patients did not use the test battery at baseline but had at least one test period of assessments thereafter. Hence, n=23 in the LCIG-naïve group. In total, symptom assessments in the full sample (including both patient groups) were collected during 379 test periods and 10079 test occasions. For 369 of these test periods, clinical assessments including UPDRS and PDQ-39 were performed in afternoons at the start of the test periods. The repeated measurements of the test battery were processed and summarized into scores representing patients' symptom severities over a test period, using statistical methods [4] . Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. In addition, an 'overall test score' (OTS) was defined to represent the global health condition of the patient during a test period.
STATISTICAL METHODS
Change in the test battery scores over time, that is at baseline and follow-up test periods, was assessed with linear mixed-effects models with patient ID as a random effect and test period as a fixed effect of interest. The within-patient variability of OTS was assessed using intra-class correlation coefficient (ICC), for the two patient groups. Correlations between clinical rating scores and test battery scores were assessed using Spearman's rank correlations (rho).
RESULTS
In LCIG-naïve patients, mean OTS compared to baseline was significantly improved from the first test period on LCIG treatment until month 24 (Fig 2) . However, there were no significant changes in mean OTS scores of LCIG-non-naïve patients, except for worse mean OTS at month 36 (p<0.01, n=16). Mean dimension scores of LCIG-naïve patients from baseline to the 36-month follow-up are shown in Figure 3 . The mean scores of all subjectively-reported dimensions improved significantly throughout the course of the study, except 'walking' at month 36 (p=0.41, n=4). However, there were no significant differences in mean scores of objectively-measured dimensions between baseline and other test periods, except improved 'tapping' at month 6 and month 36, and 'spiral' at month 3 (p<0.05). The LCIG-naïve patients had a higher within-subject variability in their OTS scores (ICC=0.67) compared to LCIG-non-naïve patients (ICC=0.71). The OTS correlated adequately with total UPDRS (rho=0.59) and total PDQ-39 (rho=0.59), (see Table 2 ).
LCIG-naïve LCIG-non-naïve Combined
Patients (n, gender) 37 (23m; 14f) 40 (27m; 13f) 77 (50m; 27f)
Age (years) 63 ± 10 65.5 ± 10 65 ± 11
Years with levodopa 10 ± 5 15 ± 8.25 13 ± 7
Years with LCIG n.a. Trends of mean OTS scores of LCIG-naïve and non-naïve patients over the 36 month study period. A high OTS score means good function. P-values are shown with respect to initial test periods; baseline for LCIG-naïve patients and month 0 for LCIG-non-naïve. One symbol (*) stands for p < 0.05, two symbols for p < 0.01 and three symbols for p < 0.001. Abbreviation: n.s., not significant. Test period (LCIG-naïve): -3, baseline (n=20); 0 (n=19); 3 (n=19); 6 (n=16); 9 (n=16); 12 (n=16); 18 (n=15); 24 (n=13); 30 (n=9); 36 (n=4). Test period (LCIG-non-naïve): 0 (n=35); 3 (n=32); 6 (n=30); 9 (n=26); 12 (n=25); 18 (n=24); 24 (n=20); 30 (n=14); 36 (n=16). Note that the last two test periods, that is month 30 and 36, had small number of reports making conclusions from these test periods difficult. 
